



Commissioner for Patents
Washington, D.C. 20231

THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 23 2002

TECH CENTER 1600/2900

16368
#14/B 58
7/28/02

In re PATENT APPLICATION of

Inventors **Catherine GUENTHER**

Appln. No.: **09/811,361**

Filed: **March 16, 2001**

Title: **TRANSGENIC MICE CONTAINING RETINA-SPECIFIC
NUCLEAR RECEPTOR GENE DISRUPTIONS**

Group Art Unit: **1636**

Examiner: **Qian, Celine X.**

Docket/Order #: **R-125**

Deposit Acct **50-1271**

Customer # **26619**

Date: **July 11, 2002**

AMENDMENT TRANSMITTAL

Sir:

Please file the enclosed amendment in the above-identified application. The signature below is to be treated as the signature to the enclosure in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity previously claimed

	Claims remaining	Highest # paid for	Present Extra	Small Entity	Add'l Fee	Fee Code
2. Total Claims	13	minus 47	0	x \$9. =	+ 0	203
3. Independent Claims	7	minus 16	0	x 42. =	+ 0	202
4. If amendment enters multiple dependent claim(s) for the first..... add				+ \$140. =	+ 0	204
5. Original due date: June 11, 2002						
6. Petition is hereby made to extend the due date to cover the date this response is filed, for which the requisite fee is enclosed				1 mo \$55 2 mos \$200 3 mos \$460 =	55.00	215 216 217
7. Enter any previous extension fee paid and (subtract)-						
8. Total fee for extension of time: +						
9. If Terminal Disclaimer is enclosed, add Rule 20(d) official fee.....				+ \$55. =	+ 248	
10. If IDS enclosed requires Official Fee, add				+ \$180. =	+ 126	
or if Rule 97(d) Petition, add				+ \$130. =	+ 122	
11. After-Final Request Fee per Rules 129(a) and 17(r).....				+ \$370. =	+ 246	
12. No. of additional inventions for examination per Rule 129(b):..... ea				x \$370. =	+ 249	
13. Petition fee for						
TOTAL FEE: <input checked="" type="checkbox"/> CHARGE AUTHORIZATION <input type="checkbox"/> ENCLOSED =					\$ 55.00	

Charge Statement: The Commissioner is hereby authorized to charge any missing or insufficient fees relative to this application, or credit any overpayment, to our Account/Order Nos. above, for which purpose a duplicate copy of this sheet is enclosed.

DELTAGEN, INC.

740 Bay Road
Redwood City, CA 94063
Tel: (650) 569-5100
Fax: (650) 569-5280

Mariette A. Lapi
MARIETTE A. LAPIZ, Reg. No. 44,202

**COPY OF PAPERS
ORIGINALLY FILED**

CERTIFICATE OF MAILING Under 37 C.F.R. 1.8

I certify that this paper and listed enclosures are being deposited with the U.S. Post Office as First Class Mail with sufficient postage in an envelope addressed to: Commissioner for Patents, BOX AMENDMENT, Washington, D.C. 20231 on July 11, 2002

Deborah A. Mojarro

Deborah A. Mojarro



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JUL 23 2002
TECH CENTER 1600/2900

Application of: Catherine Guenther

Group Art Unit: 1636

Serial No.: 09/811,361

Examiner: Qian, Celine X

Filed: March 16, 2001

Attorney Docket No.: R-125

For: **TRANSGENIC MICE CONTAINING RETINA-SPECIFIC NUCLEAR RECEPTOR
GENE DISRUPTIONS**

AMENDMENT

**COPY OF PAPERS
ORIGINALLY FILED**

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated March 11, 2002, in connection with the above-identified application, Applicants respectfully request entry and consideration of the following amendments and remarks. Applicants submit concurrently herewith a Petition for the Extension of Time under 37 CFR 1.136(a) for response to the Office Action for a period of one month from June 11, 2002 up to and including July 11, 2002.

THE AMENDMENTS

In the Claims:

Please cancel claims 1-10 and 17-24.

Please add new claims 38-50 as follows:

38. (New) A targeting construct comprising:
- (a) a first polynucleotide sequence homologous to a first region of a retina-specific nuclear receptor gene;
 - (b) a second polynucleotide sequence homologous to a second region of the retina-specific nuclear receptor gene; and

07/22/2002 SSESHE1 00000058 501271 09811361

01 FC:215

55.00 CH